Pilot Tape Harvesting Study

No study drug is administered as part of this study. All participants except healthy
volunteers will be treated according to standard clinical practice.

Key Inclusion Criteria:

- Healthy volunteers must be in good overall health as determined by the Investigator,
based on medical history, physical examination (per standard dermatology practice),
and vital signs.

- Subjects with lupus must present with active DLE or SCLE skin disease (with or
without systemic manifestations of SLE, as defined by ≥4 out of 11 classification
criteria for SLE).

- Subjects with AD must have been diagnosed by the Eichenfield revised criteria of
Hanifin and Rajka, disease duration for at least 2 years before Screening and disease
activity defined as Investigator's Global Assessment (IGA) score ≥3 at screening

Key Exclusion Criteria:

- History of severe allergic or anaphylactic reactions or history of allergic reactions
likely to be exacerbated by tape harvesting (e.g., allergy to adhesives).

- Other unspecified reasons that, in the opinion of the Investigator, make the subject
unsuitable for enrollment.

Key Exclusion Criteria for Healthy Volunteers

- History of any clinically significant medical condition, as determined by the
Investigator, that may impact study analyses

Key Exclusion Criteria for Subjects with Discoid or Subacute Cutaneous Lupus:

- Evidence of skin conditions other than DLE or SCLE at the Day 1 Visit that, in the
opinion of the Investigator, would interfere with the study execution or analysis.

- History of malignancy in the last 5 years (nonmelanoma skin cancer that is considered
cured by the Investigator will not be exclusionary).

Key Exclusion Criteria for Subjects With Atopic Dermatitis:

- History of any clinically significant medical condition, other than AD, as determined
by the Investigator, that may impact study analyses, including, but not limited to:
History of human immunodeficiency virus; History of hepatitis C virus or hepatitis B
virus infection; Symptoms of bacterial or viral infection (including skin infection)
within 14 days prior to the Day 1 Visit; History of malignancy in the last 5 years
(nonmelanoma skin cancer that is considered cured by the Investigator will not be
exclusionary).

- Evidence of skin conditions other than AD at the Day 1 Visit that, in the opinion of
the Investigator, would interfere with the study execution or analysis.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.